Roger Garceau
Director/Board Member at ENTERA BIO LTD.
Net worth: 140 580 $ as of 2024-03-30
Profile
Roger J.
Garceau is currently serving as an Independent Director at Enterome SA since 2016, as a Director at Entera Bio Ltd.
since 2016, as a Director at Fluorinov Pharmaceuticals, Inc. since 2015, and as an Independent Director at Protara Therapeutics, Inc. since 2019.
Previously, he held the position of Director at ArTara Subsidiary, Inc. and served as the Chief Medical Officer & Executive Vice President at NPS Pharmaceuticals, Inc. from 2014 to 2015.
Dr. Garceau completed his undergraduate studies at Fairfield University and obtained a doctorate degree from UMass Chan Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-06-06 | 33,000 ( 0.29% ) | 132 330 $ | 2024-03-30 | |
ENTERA BIO LTD.
0.01% | 2024-02-29 | 4,940 ( 0.01% ) | 8 250 $ | 2024-03-30 |
Roger Garceau active positions
| Companies | Position | Start |
|---|---|---|
| ENTERA BIO LTD. | Director/Board Member | 2016-02-29 |
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 2018-12-31 |
Fluorinov Pharmaceuticals, Inc.
 Fluorinov Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fluorinov Pharmaceuticals, Inc. manufactures pharmaceutical products. The American company was founded by Abdelmalik Slassi. | Director/Board Member | 2015-05-03 |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Director/Board Member | 2016-11-30 |
Former positions of Roger Garceau
| Companies | Position | End |
|---|---|---|
| NPS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2015-01-31 |
ArTara Subsidiary, Inc.
 ArTara Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. | Director/Board Member | - |
Training of Roger Garceau
| Fairfield University | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENTERA BIO LTD. | Health Technology |
| Private companies | 5 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Fluorinov Pharmaceuticals, Inc.
Fluorinov Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fluorinov Pharmaceuticals, Inc. manufactures pharmaceutical products. The American company was founded by Abdelmalik Slassi. | Health Technology |
ArTara Subsidiary, Inc.
ArTara Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. | Health Technology |
| Protara Therapeutics, Inc. |
- Stock Market
- Insiders
- Roger Garceau
